Form 4: Altimmune CFO's RSU Vesting and Tax-Related Stock Sale

Altimmune's CFO, Gregory L. Weaver, reported the vesting of 18,750 Restricted Stock Units and a subsequent sale of 5,672 shares to cover tax obligations.

Summary

• Gregory L. Weaver, Chief Financial Officer of Altimmune, Inc., reported changes in his beneficial ownership of company stock.
• On November 11, 2025, 18,750 Restricted Stock Units (RSUs) vested, converting into an equal number of common shares.
• Concurrently, 5,672 shares of common stock were disposed of at a price of $4.28 per share to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Mr. Weaver directly beneficially owns 23,078 shares of common stock.
• Additionally, Mr. Weaver holds 56,250 unvested Restricted Stock Units.

Sentiment

Score: 6

Explanation: The filing reports a routine, pre-scheduled RSU vesting event for an executive, which is a positive for the individual's compensation. The associated tax-related sale is a standard procedure and does not reflect negatively on the company's performance or outlook.

Positives

• The vesting of 18,750 Restricted Stock Units represents a scheduled compensation event for the Chief Financial Officer, increasing his direct ownership of common stock.

Negatives

• A disposition of 5,672 shares of common stock occurred to satisfy tax withholding obligations, reducing the number of shares beneficially owned after vesting.

Future Outlook

This filing does not provide forward-looking statements or guidance regarding the company's operations or financial performance.

Industry Context

This Form 4 filing details a routine insider transaction and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: This is a routine insider transaction and is unlikely to have a significant impact on the broader shareholder base or stock price.
• Employees: The RSU vesting reflects standard executive compensation practices.

Next Steps

• The remaining 56,250 Restricted Stock Units will vest in equal annual installments over the next three years, subject to the reporting person's continued service.

Key Dates

Keywords

Altimmune, ALT, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Chief Financial Officer, Stock Sale, Tax Withholding